Brief: Clarity Pharmaceuticals Says It Got IND Approval By U.S. FDA For Phase II SAR-Bombesin Trial
06/06/2022 02:52
June 6 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* IND APPROVAL BY US FDA FOR PHASE II SAR-BOMBESIN
TRIAL-CU6.AX
Source text for Eikon: ID:nASXbcXF1H
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial